Study demonstrates that the BNT162b2 SARS-CoV-2 XBB1.5 variant-modified vaccine significantly reduces the risk of COVID-19-related hospitalizations and ambulatory visits, outperforming previous vaccine versions in the face of evolving virus strains.
Following injection side effects, Design Therapeutics to reformulate Friedreich’s ataxia drug, delay trial timeline
Design Therapeutics said Tuesday morning that it was planning to reformulate its Friedreich’s ataxia drug following injection site reactions in a Phase I study. As